API TB consensus guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations

Journal of Association of Physicians of India

Volumn 54, Issue MAR., 2006, Pages 219-234

  Joshi, J M ^a   Vijayan, V K ^b,c   Jindal, S K ^d   Jagganath, K ^e,f   Rodrigues, Camilla ^g   Gupta, S B ^h,i  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

^b UNIVERSITY OF DELHI   (India)

^c NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^d POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^e Chennai Research Institute   (India)

^f Institute of Thoracic Medicine   (India)

^g P D HINDUJA NATIONAL HOSPITAL   (India)

^h Baba Saheb Ambedkar Memorial Hospital   (India)

ⁱ API ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ALGORITHM; CONFERENCE PAPER; HUMAN; LUNG TUBERCULOSIS; MICROBIOLOGY; PRACTICE GUIDELINE; WORLD HEALTH ORGANIZATION;

ALGORITHMS; ANTITUBERCULAR AGENTS; HUMANS; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 33645145275     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Toman K. Tuberculosis case Finding and Chemotherapy: Questions and answers Geneva WHO 1979.
2. Uplekar MV, Rangan S. Private doctors and tuberculosis control in India. Tuber Lung Disease 1993;74:332-7.
3. Stefan G. Tuberculosis in the third world. Editorial Thorax 1991;46: 689-91.
4. John RW, Bhattacharya M, Kleper NF, et al. A minimum 5.0 ml of sputum improves the sensitivity of acid-fast smear for Mycobacterium tuberculosis. Am J Respir Crit Care Med 2000;161:1559-62.
5. Gothi D, Joshi J M. Clinical and Laboratory Observations on Tuberculosis at a Mumbai (India) Clinic. Pastgrad Med J 2004;80:97-100.
6. Woods GL. The mycobacteriology laboratory and new diagnostic techniques. Infect Dis Clin of North Am 2002; 16:127-44.
7. Somu N, Swaminathan S, Paramasivan CN, Vijayasekaran D, Chandrabhooshanam A, Vijayan VK, Prabhakar R. Value of bronchoalveolar lavage and gastric lavage in the diagnosis of pulmonary tuberculosis in children. Tuber Lung Dis 1995;76:295-9.
8. Vasanthakumari R, Jagannath K. Brief communication: rapid culture of tubercle bacilli. Bull World Health Organ 1998;76:309-11.
9. Tenover FC, Crawford JT, Heubner RE, Ceiter LF, Harsburgh CR, Good RC. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993;31:767-70.
10. Nitta AT, Davidson PT, deKong ML, Kilman RJ. Misdiagnosis of multidrug resistant tuberculosis possibly due to laboratory related errors. JAMA 1996;276:1980-3.
11. Saba x AT, Perrenne C, Lacessin F, Lunguel - P Leport C, Vilde JC - Emperic anti-tuberculosis treatment, benefit for early diagnosis and treatment of tuberculosis. Tubercle and lung Disease 1994;75:334-40.
12. Amin NM. Tuberculin Skin testing: Can it contain the impending tuberculosis epidemic? Post Grad Med. 1994;95:46-56.
13. Pai M Alternatives to the tuberculin Skin Test: Interferon -3 assays in the diagnosis of Mycobacterium tuberculosis infection. Ind J Med Microbiol 2005;23:151-8.
14. Cocito, Properties of the mycobacterial antigen complex A60 and its application to the diagnosis and prognosis of tuberculosis. Chest 1991;100:1687-9.
15. Pai M. Kalantri S, Pascopella L, Riley L and Reingold A. Bacteriophage-based tests for the detection of Mycobacterium tuberculosis in clinical specimens: a systemic review and meta-analysis. BMC Inf Dis 2005:5;59.
16. Shenai S, Rodrigues C, Almeida A and Mehta AP. Rapid diagnosis of tuberculosis using Transcription Mediated Amplification. IJMM 2001;19: 184-9.
17. Pai M. Flores L, Pai N, Hubbard A, Riley L and Colford JM. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systemic review and meta-analysis. The Lancet Inf Dis 2003;3:633-43.
18. Girling DJ, Coolet P. Anti-tuberculosis regimens of Chemotherapy. Recommendations from the committee on treatment of International union against tuberculosis and lung disease. Indian J Chest Disease, and Allied Science 1988;30:296-304.
19. American thoracic Society Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990;192:725-35.
20. Guidelines for management of drug resistant tuberculosis. WHO / TB / 96.210.Treatment for Tuberculosis. Guidelines for National Programmes. Geneva. WHO/ TB/97.220.
21. A joint statement of the International Union against Tuberculosis and Lung Diseases and the tuberculosis programme of the WHO. Tubercle and Lung Disease 1994;75:180-1.
22. Allen MB, Cooka NJ. Corticosteroids and tuberculosis. Br Med J 1991;303:871-2.
23. st Edition, Chapman and Hall (London) 93-125.
24. Campbell IA. The treatment of superficial tuberculous lymphadenitis. Tubercle 1990;71:l-3.
25. Davison DT, Le HL Drug treatment of tuberculosis-1992 Drugs 1992;43: 651-73.
26. th world conference of the IUATLD / UICTMR. Bangkok, Thailand, 1998.
27. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tub Lung Dis 1995;76:109-113.
28. Burman W J, Jones B E. Treatment of HIV related Tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001;164:7-12.
29. Pablos-Mendez A, Biokin N,Rieder HL, et al. Global surveillance for antituberculosis drug resistance, 1994 -1997. World Health Organization - International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Eng J Med 1998;338:1641-50.
30. Mitchison DA. Role of individual drug in chemotherapy of tuberculosis. Int J Tuber Lung Disease 2000;4:790-800.
31. Parthasarathy R, Darma GR, Janardhanam B et al. Hepatic toxicity in S. Indian patients during treatment of tuberculosis with short course regimens containing isoniazid, rifampicin and pyrazinamide, Tubercle, 1986; 67: 98-108.
32. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment - induced hepatotoxicity: Role of predictive factors. Post Grad Med J 1996; 71:359-62.
33. Mirchandani LV, Joshi JM. Jaundice due to antituberculosis drugs- a dose related phenomenon. J Assoc Phy India 1995;43:767-9.
34. The Revised National TB Control Programme and the DOTS strategy Excerpts from an Observational Study in Three Districts Dr Sunil Kaul, 1998. www.ctrlaltesc.org/fighttb/02/02/11/102207.shtml.
35. Balasubramanium VN, Dommen K, Samuel R. DOT or not? Direct observation of anti tuberculosis treatment and patient outcomes, Kerala State, India. Int J Tuberc Lung Dis 2000;4:409-13.
36. Santha T, Garg R, Frieden TR, Chandrasekaran V, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000 Int J Tuber Lung Dis 2002;6:780-8.
37. DOTS-Plus Green Light Committee WHO/CDS/TB/2000.283.
38. Treatment of tuberculosis. Guidelines for National Programmes. Third Edition. WHO 2003. Geneva, WHO/CD5/TB 2003.313.
39. WHO/CDS/TB/2003.313 Treatment of tuberculosis: guidelines for national programmes, third edition. Revision approved by STAG, June 2004.
40. Iseman MD. A leap of faith what can we do to curtail intrainstitutional transmission of tuberculosis. Ann Intern Med 1992;117:251-3.
41. Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Experience with ARDS caused by tuberculosis in a respiratory intensive care unit. Intensive Care Med. 2005 Jul 9; [Epub ahead of print]
42. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis. WHO /TB / 96.210.
43. Di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004;54:593-602.